Angina Pectoris Drugs Market Size and ForecastThe global angina pectoris drugs market is poised for substantial growth over ...

Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...

Cytosorbents Corporation (CTSO) reports 25% Q4 revenue growth, strong margins, and updates on FDA-reviewed DrugSorb-ATR launch.

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...

A step forward in de-escalating treatment The evolution of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has been shaped by the continuous challenge of balancing ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

The top 10 drugs losing US exclusivity in 2025 After patent settlement, Amgen scores FDA nod for its biosimilar version of J&J's Stelara Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch ...

Further research revealed that one of these drugs, DDL-920 – developed at UCLA, led to the complete recovery of movement control – something many stroke patients never regain.